Novo-Nordisk stock heads into the open after a sharp 3.1 percent drop

At the close on September 8, 2026, Novo-Nordisk stock finished around USD 45 on its US listing after losing 3.1 percent, with the shares trading well below some valuation estimates. Trading volume was elevated as investors reacted to clinical trial news and wider market pressure.

Novo-Nordisk stock closed at USD 45.16 on its US listing on September 8, 2026, down 3.1 percent from the previous session, according to market data cited by GuruFocus for Novo Nordisk AS American depositary shares.

September 8, 2026 in numbers

Novo Nordisk Inc. (ISIN DK0062498333) saw its American depositary shares finish the September 8, 2026 session at USD 45.16, with the price move described as a 3.1 percent decline in a market wrap by GuruFocus on September 8, 2026. The same report framed the move against a GF Value estimate of USD 108.37, implying that the close of USD 45.16 stood roughly 58.3 percent below that valuation metric.

In a separate note on September 8, 2026, GuruFocus highlighted that Novo Nordisk shares around USD 46.60 were trading roughly 56 percent below a GF Value of USD 105.83, reinforcing how far the stock remained from that modeled fair value. The articles described the shares as significantly undervalued on that basis and noted that the dividend profile remained a key attraction for some investors, even after the recent pullback.

Today's drivers and events

Looking ahead to today, September 9, 2026, investors face the US session after the prior day's risk-off tone, with broader US equity benchmarks having slipped on September 8, 2026 as oil prices rose and healthcare names came under pressure, according to a Wall Street recap by Pittsburgh Post-Gazette. Against that backdrop, Novo-Nordisk stock enters today's trading day with a recent loss and a wide gap to some valuation models, while investors continue to monitor sector sentiment and any further company-specific clinical or regulatory news that could influence the shares.